Skip to main content

Desarrollo de una herramiento de predicción de respuesta a terapia biológica en niños con enfermedad inflamatoria intestinal

PI22/00584

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INVESTIGACION BIOMEDICA HOSPITAL GREGORIO MARAÑON
Execution centre FUNDACION INVESTIGACION BIOMEDICA HOSPITAL GREGORIO MARAÑON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment

  • Salvador-Martín, Sara
  • Rubbini, Gianluca
  • Vellosillo, Perceval
  • Zapata-Cobo, Paula|||0000-0003-1907-1709
  • Velasco, Marta
  • Palomino, Laura M.
  • Clemente, Susana|||0000-0001-6272-6438
  • Segarra Canton, Oscar|||0000-0003-2162-1474
  • Moreno-Álvarez, Ana
  • Fernández-Lorenzo, Ana|||0000-0002-8611-5735
  • Pérez-Moneo, Begoña|||0000-0002-7335-848X
  • Montraveta Querol, Maria Montserrat|||0000-0003-3983-5374
  • Sánchez, Cesar
  • Tolín, Mar
  • Loverdos, Inés|||0000-0002-5496-8717
  • Fobelo, María José
  • Navas-López, Víctor Manuel
  • Magallares, Lorena
  • García-Romero, Ruth
  • Torres-Peral, Ricardo
  • Rodríguez, Alejandro
  • Bossacoma, Ferrán
  • Merino-Bohórquez, V.
  • Salcedo, Enrique
  • Álvarez, Rebeca
  • Dopazo, Ana
  • Sanjurjo Sáez, María|||0000-0002-8523-3721
  • Lopez-Fernandez, Luis A.|||0000-0003-3964-5837
Background/aims: Changes in gene expression profiles among individuals with inflammatory bowel diseases (IBDs) could potentially influence the responsiveness to anti-TNF treatment. The aim of this study was to identify genes that could serve as predictors of early response to anti-TNF therapies in pediatric IBD patients prior to the initiation of treatment. Methods: We conducted a prospective, longitudinal, and multicenter study, enrolling 24 pediatric IBD patients aged less than 18 years who were initiating treatment with either infliximab or adalimumab. RNA-seq from blood samples was analyzed using the DESeq2 library by comparing responders and non-responders to anti-TNF drugs. Results: Bioinformatic analyses unveiled 102 differentially expressed genes, with 99 genes exhibiting higher expression in responders compared to non-responders prior to the initiation of anti-TNF therapy. Functional enrichment analyses highlighted defense response to Gram-negative bacteria (FDR = 2.3 ×10-7) as the most significant biological processes, and hemoglobin binding (FDR = 0.002), as the most significant molecular function. Gene Set Enrichment Analysis (GSEA) revealed notable enrichment in transcriptional misregulation in cancer (FDR = 0.016). Notably, 13 genes (CEACAM8, CEACAM6, CILP2, COL17A1, OLFM4, INHBA, LCN2, LTF, MMP8, DEFA4, PRTN3, AZU1, and ELANE) were selected for validation, and a consistent trend of increased expression in responders prior to drug administration was observed for most of these genes, with findings for 4 of them being statistically significant (CEACAM8, LCN2, LTF2, and PRTN3). Conclusions: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs.